Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

2.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

3.
4.

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.

Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK.

Am J Kidney Dis. 2005 Oct;46(4):713-9.

PMID:
16183427
6.

Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.

Franko A, Neschen S, Rozman J, Rathkolb B, Aichler M, Feuchtinger A, Brachthäuser L, Neff F, Kovarova M, Wolf E, Fuchs H, Häring HU, Peter A, Hrabě de Angelis M.

Mol Metab. 2017 Jan 6;6(3):256-266. doi: 10.1016/j.molmet.2016.12.007. eCollection 2017 Mar.

8.
9.

Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies.

Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL.

Cardiovasc Diabetol. 2009 Apr 15;8:20. doi: 10.1186/1475-2840-8-20.

10.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174. Epub 2010 Oct 28.

PMID:
21031343
12.

The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.

Kavak S, Ayaz L, Emre M, Inal T, Tamer L, Günay I.

Cell Biochem Funct. 2008 Jun;26(4):478-85. doi: 10.1002/cbf.1469.

PMID:
18348180
13.

[The effects of rosiglitazone combined ceftazidime on peroxisome proliferator activated receptor γ activity and interleukin in septic rats].

Zeng M, Huang XM, He WM, Chen H, Jiang YJ.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Sep;24(9):550-3. Chinese.

14.
15.

[Rosiglitazone(BRL-49653)].

Yonezawa N, Oka Y.

Nihon Rinsho. 2001 Nov;59(11):2195-9. Review. Japanese.

PMID:
11712407
16.

Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.

Hsu WH, Chen TH, Lee BH, Hsu YW, Pan TM.

Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22.

PMID:
24275089
17.

Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice.

Franko A, Huypens P, Neschen S, Irmler M, Rozman J, Rathkolb B, Neff F, Prehn C, Dubois G, Baumann M, Massinger R, Gradinger D, Przemeck GK, Repp B, Aichler M, Feuchtinger A, Schommers P, Stöhr O, Sanchez-Lasheras C, Adamski J, Peter A, Prokisch H, Beckers J, Walch AK, Fuchs H, Wolf E, Schubert M, Wiesner RJ, Hrabě de Angelis M.

Diabetes. 2016 Sep;65(9):2540-52. doi: 10.2337/db15-1670. Epub 2016 Jun 9.

18.

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.

Yu D, Murdoch SJ, Parikh SJ, Marcovina SM, Cobitz A, Chen H, Brunzell JD.

Diab Vasc Dis Res. 2006 Dec;3(3):189-96.

PMID:
17160915
19.

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.

Diabetes Obes Metab. 2008 Aug;10(8):626-37. Epub 2007 Jul 21.

PMID:
17645558
20.

An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.

Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M.

Int J Cardiol. 2013 Oct 9;168(4):3160-72. doi: 10.1016/j.ijcard.2013.07.150. Epub 2013 Aug 6. Review.

PMID:
23932046

Supplemental Content

Support Center